Accelerating early phase development in the UK and Germany
Recent changes in the regulatory environment post-pandemic and the introduction of EU-CTR 536/2014 are making the UK and Germany more attractive to biotech drug developers. In this video, Parexel experts provide an update on recent early-phase regulatory timelines in the UK and Germany, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies.
Also, our thought leaders answer your questions about recent changes with the MHRA and EU-CTR process, approval timelines, and the government’s efforts to make these key regions more attractive for conducting clinical trials.
Parexel Biotech can connect every step of development with you. Our Early Phase services combine clinical pharmacology and regulatory expertise to help you move swiftly and efficiently to the proof of concept milestone. Learn more about our clinical units and integrated Early Phase expertise.
Related Insights
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines
Apr 4, 2024
Blog
Regulatory outsourcing: Applying change management best practices for smoother transitions
Jul 24, 2025
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Blog
Best practices and lessons learned in a challenging IBD study
Jul 19, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Related Insights
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines
Apr 4, 2024
Blog
Regulatory outsourcing: Applying change management best practices for smoother transitions
Jul 24, 2025
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Blog
Best practices and lessons learned in a challenging IBD study
Jul 19, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023